LOS ANGELES, CA -- (Marketwired) -- 08/26/13 --
MMRGlobal, Inc. (OTCQB: MMRF) ("MMR"), a leading provider of Personal Health Records (PHRs), MyEsafeDepositBox storage solutions and electronic document management and imaging systems for healthcare professionals, today announced that as a result of the Expedited Patent Allowance Program referred to as the Patent Prosecution Highway ("PPH"), and following the issuance of U.S. patents to MMR for its anti-CD20 monoclonal antibodies, the Company has received confirmation of the filings of a divisional application for its antibody technology in Japan, No. P09277JP01, as well as the filing on August 23, 2013 of a divisional Korean patent application, No. 10-2013-7022383. These filings are in addition to the Company's recently announced filing of a divisional Chinese patent application, No. 200780051557.6, on August 15, 2013. All are similarly entitled "Antibodies and Methods for Making and Using Them." The issuance of U.S. Patent No. 8,465,741 on June 18, 2013 provided the Company with a mechanism to request expedited examination of the equivalent patent claims in various international countries. The filings are part of MMRGlobal's plan to expand the scope of its biotech assets and other intellectual property, in particular, the Company's issued U.S. Patent No. 8,465,741 directed at its anti-CD20 antibody assets, which has also been granted in Mexico and Australia.
The U.S. patent and PPH patent application will help provide additional protection of the Company's specific antibodies that have particular utility in fighting cancers. MMR's anti-CD20 monoclonal antibodies are important assets of the Company, the value and benefit of which are demonstrated by how these antibodies are used commercially in products like RituxanŽ, an anti-CD20 monoclonal antibody with reported worldwide sales of $7.285 billion in 2012 which is due to go off patent in 2015. Additional patent applications for the Company's antibodies are also pending in a number of other countries including Brazil, Canada, Hong Kong, India, and European nations. The Company's anti-CD20 antibodies were developed to help provide low-cost alternatives for treatments like RituxanŽ in connection with non-Hodgkin's lymphoma and other B-cell mediated cancers widely considered too expensive for the world population of patients who require the costlier forms of treatment to live.